A
ANI Pharmaceuticals
Manufactures oral solid dose products, as well as liquids and topicals
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products. The company serves patients in need by providing FDA-approved medications that meet stringent safety and efficacy standards. ANI Pharmaceuticals operates in the pharmaceutical industry, targeting both healthcare providers and patients as its primary clients. The business model revolves around the development and commercialization of a broad portfolio of pharmaceutical products, including specialty drugs and generics. Revenue is generated through the sale of these products to pharmacies, hospitals, and healthcare providers. The company also engages in strategic acquisitions to expand its product offerings and market reach.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1996
- Headquarters
- Baudette, United States
- Listing
- IPO 2000
- Employees
- 775
- Open positions
- 34
- Dealroom signal
- 58.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 3 companies, latest Jun 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
News
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | Aug 2024 | $316M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | May 2023 | $75M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for ANI Pharmaceuticals is 20K monthly website visits, down 28.6% over the last three months. ANI Pharmaceuticals's team grew 23.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Alimera SciencesAlpharetta, United StatesDevelops and commercializes prescription ophthalmic pharmaceuticals
$360Mvaluation
BioSante PharmaceuticalsLincolnshire, United StatesPharmacy Health | Information for Great Healthcare
$72Mvaluation
ANI Pharmaceuticals in the Baudette ecosystem
The ANI Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Citizens Bank
Other known investors2 additional known investors
Meridian Venture Partners
First Analysis
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ANI Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ANI Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.